Zaremba Rabourn Amy
SEC CIK 1832343 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | SVP of Fin | 188.7K | — | $23.3K | 10 | 2023-01-10 | 2026-04-23 |
Most active insiders at IRD, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Foundation Fighting Blindness Retinal Degeneration Fund | Dir, See Remarks | — | $15.99M |
| 2 | Gallagher Cam | Dir | $323.9K | — |
| 3 | Magrath George | CEO, Dir | — | $204.9K |
| 4 | Gagnon Robert E. | CFO | — | $190.8K |
| 5 | YERXA BENJAMIN R | Pres, Dir | — | $61.2K |
| 6 | Jayagopal Ashwath | Chief Scientific, Dev. Ofc | — | $58.2K |
| 7 | SCHACHLE JOSEPH K | COO | — | $57.7K |
| 8 | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | — | $23.3K |
| 9 | Bennett Jean | Dir | — | — |
| 10 | Ainsworth Sean | Dir | — | — |
Transactions 10
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 16:27 | 2026-04-23 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | S - Sale | $5.20 | -1,641 | 188.7K | -0.9% | -$8,540 | |
| 2026-03-18 | 2026-03-16 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | S - Sale | $5.25 | -2,816 | 190.3K | -1% | -$14.8K | |
| 2026-01-26 | 2026-01-22 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | A - Grant | $0.00 | +86.5K | 193.1K | +81% | $0 | |
| 2026-01-21 | 2026-01-18 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | F - Tax | $2.10 | -3,390 | 106.6K | -3% | -$7,119 | |
| 2026-01-13 | 2026-01-10 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | F - Tax | $1.93 | -3,950 | 110.0K | -3% | -$7,624 | |
| D | 2025-03-17 | 2025-03-13 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | SVP of Fin | A - Grant | $0.00 | +39.5K | 114.0K | +53% | $0 |
| 2025-02-06 | 2025-02-04 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | SVP of Fin | F - Tax | $1.14 | -8,190 | 74.5K | -10% | -$9,337 | |
| D | 2024-01-22 | 2024-01-18 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | SVP of Fin | A - Grant | $0.00 | +40.0K | 82.7K | +94% | $0 |
| 2024-01-12 | 2024-01-10 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | SVP of Fin | F - Tax | $3.27 | -3,950 | 42.7K | -8% | -$12.9K | |
| D | 2023-01-12 | 2023-01-10 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | SVP of Fin | A - Grant | $0.00 | +46.6K | 46.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations